Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats

Merodio, Marta; Irache, Juan M.; Valamanesh, F.; Mirshahi, Massoud

doi:10.1016/s0142-9612(01)00284-8

Cited by 119 publications

(53 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A 2 4 -factorial central composite experimental design, with eight axial points and seven replications at the center points leading to a total number of 31 experiments was employed for the optimization of the parameters (38). The variables were coded according to the following equation:…”

Section: Nanoparticles Pegylation Optimizationmentioning

confidence: 99%

“…Among them, nanoparticulate systems based on proteins have gained much interest because of their inherent properties of biodegradability, lack of toxicity, and nonantigenicity (1,2). Protein nanoparticles may be used as a matrix in which a wide variety of drugs can be physically entrapped (3)(4)(5). In contrast to other nanoparticulate systems, they offer the benefit of carrying functional groups such as amino and carboxylic groups that can be used for surface modification (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology

et al. 2010

View full text Add to dashboard Cite

Abstract. Chemical coupling of polyethylene glycol (PEG) to proteins or particles (PEGylation), prolongs their circulation half-life by greater than 50-fold, reduces their immunogenicity, and also promotes their accumulation in tumors due to enhanced permeability and retention effect. Herein, phase separation method was used to prepare bovine serum albumin (BSA) nanoparticles. PEGylation of BSA nanoparticles was performed by SPA activated mPEG through their free amino groups. Effect of process variables on PEGylation efficiency of BSA nanoparticles was investigated and optimized through response surface methodology with the amount of free amino groups as response. Optimum conditions was found to be 32.5 g/l of PEG concentration, PEG-nanoparticle incubation time of 10 min, incubation temperature of 27°C, and pH of 7 for 5 mg of BSA nanoparticles in 1 mL phosphate buffer. Analysis of data showed that PEG concentration had the most noticeable effect on the amount of PEGylated amino groups, but pH had the least. Mean diameter and zeta potential of PEGylated nanoparticles under these conditions were 217 nm and −14 mV, respectively. In conclusion, PEGylated nanoparticles demonstrated reduction of the negative surface charge compared to the non modified particles with the zeta potential of −31.7 mV. Drug release from PEGylated nanoparticles was almost slower than non-PEGylated ones, probably due to existence of a PEG layer around PEGylated particles which makes an extra resistance in opposition to drug diffusion.

show abstract

Section: Nanoparticles Pegylation Optimizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Colloidal systems based on proteins might be incredibly promising as they unite the advantages of nanoparticles with the advantages of covalent protein-drug conjugates (5,6). Protein nanoparticles, due to the existence of charged groups, may also be used as a matrix in which drugs can be physically entrapped (7)(8)(9). Albumin, being widespread in nature, is an attractive macromolecular carrier and has been a subject of major interest.…”

Section: Introductionmentioning

confidence: 99%

5-Fluorouracil-Loaded BSA Nanoparticles: Formulation Optimization and In Vitro Release Study

2008

View full text Add to dashboard Cite

Abstract. Over the past few decades, there has been considerable interest in developing protein nanoparticles as drug delivery devices. The underlying rationale is their exceptional characteristics, namely biodegradability and nonantigenicity. Herein, phase separation method was used to prepare 5-fluorouracil-loaded bovine serum albumin (BSA) nanoparticles. Drug release was tracked by continuous flow dialysis technique. Effect of process variables on loading efficiency of 5-fluorouracil was investigated and optimized through Taguchi's M16 design with the amount of entrapped drug as response. Optimum condition was found to be 2 mg/mL of 5-fluorouracil, 3.7 mL of added ethanol, 176 µL of glutaraldehyde, drug-protein incubation time of 30 min, and pH of 8.4 for 200 mg of BSA in 2 mL drug solution. pH had the most noticeable effect on the amount of entrapped drug, but glutaraldehyde had the least. Mean diameter and zeta potential of fabricated nanoparticles under these conditions were 210 nm and −31.7 mV, respectively. Drug-loaded BSA nanoparticles suspension maintained constant release of drug for 20 h under experimental conditions, so this colloidal drug carrier is capable of releasing drug in a sustained manner.

show abstract

“…In fact, one study has evaluated the ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injections in rats (Merodio et al 2002). Albumin nanoparticles were detected in the vitreous up to 2 weeks after injection, and the histopathology of the retina, ciliary muscle, neuronal interplay area, outer and inner nuclear layers, and the vitreous cavity showed no signs of inflammation after 2 weeks.…”

Section: Protein Nanoparticlesmentioning

confidence: 99%

Nanotechnology and Nanoparticles

Durazo

Kompella

2011

AAPS Advances in the Pharmaceutical Sciences Series

View full text Add to dashboard Cite

Developing effective therapeutics to treat disorders of the back of the eye is an extremely difficult task due to the inability to deliver therapeutically relevant drug levels to the back of the eye using traditional methods (topical and systemic modes of administration). Innovative techniques and approaches are required to overcome the limitations associated with developing effective therapeutics to treat disorders of the back of the eye. Nanotechnology is a field that advances materials with a nano-dimension and provides several means for innovative design of nanosize drug delivery systems (nanosystems) to overcome biological barriers. Nanosystems based on polymers, lipids, proteins, and carbohydrates hold significant promise in enhancing drug delivery and hence, efficacy of small as well as large molecules intended for treating disorders of the back of the eye.

show abstract

Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats

Cited by 119 publications

References 24 publications

Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology

Optimization of PEGylation Conditions for BSA Nanoparticles Using Response Surface Methodology

5-Fluorouracil-Loaded BSA Nanoparticles: Formulation Optimization and In Vitro Release Study

Nanotechnology and Nanoparticles

Contact Info

Product

Resources

About